Greg Yap brings nearly 20 years of operating experience from companies like Illumina and Ventana/Roche to his venture investing at Menlo Ventures, giving him hands-on knowledge of regulatory science, lab workflows, and clinical adoption that most VCs lack. He has created a formal "5 Ps of Therapeutics Investing" framework and leads Menlo's focus on companies where biology and advanced computation are combined from day one, rather than traditional therapeutics alone.

• Championing the intersection of computational power and biology to accelerate drug discovery. He frequently highlights how foundation models are revolutionizing antibody design and protein engineering, citing the progress of portfolio companies like Chai Discovery and the Nobel Prize-winning work associated with founders of Xaira Therapeutics.
• Focus on the specific infrastructure stack required to deploy reliable generative AI within enterprises. He outlines a technical architecture that combines data ingestion, vector databases, and language models to improve accuracy, specifically recommending tools like UnstructuredIO for data processing alongside Pinecone and Anthropic.
• Deep interest in digital health platforms that address severe mental health crises and care delivery. He actively supports ventures tackling complex societal issues, such as Cartwheel Care for youth mental health services and Ophelia for treating opioid addiction.
• Tracking AI adoption rates across different industries to identify market leaders. He regularly shares firm-generated research indicating that the healthcare sector is currently outpacing other verticals in implementing artificial intelligence, with providers leading the charge over other business categories.
• Enthusiasm for autonomous agents as the primary vehicle for future AI utility. He posits that agents capable of executing tasks will be the main way users benefit from the technology, encouraging founders building agent-based architecture and applications to connect with his firm.